mHSPC: Applying Data Toward Treatment Decision-Making

Opinion
Video

Evan Y. Yu, MD, discusses how community oncologists can critically weigh the evidence from studies on androgen deprivation therapy plus androgen receptor pathway inhibitors regimens by considering factors such as efficacy, safety, patient comorbidities, and treatment preferences, and how the collective trial results guide individualized treatment decision-making to optimize outcomes for patients with metastatic hormone-sensitive prostate cancer.

Recent Videos
1 expert in this video
1 expert in this video
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content